Gilead Sciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GILD research report →
Range $126 – $196
Price Chart
About the company
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs.
- CEO
- Daniel O'Day
- IPO
- 1992
- Employees
- 17,000
- HQ
- Foster City, CA, US
Get TickerSpark's AI analysis on GILD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $206.43B
- P/E
- -54.92
- Fwd P/E
- 16.40
- PEG
- 0.42
- P/S
- 6.81
- P/B
- 16.22
- EV/EBITDA
- 179.05
- Div Yield
- 1.91%
- Gross Margin
- 79.93%
- Op Margin
- 34.51%
- Net Margin
- -12.47%
- ROE
- -21.74%
- ROIC
- 25.57%
Latest fiscal year · YoY change
- Revenue
- $29.44B+2.4%
- Gross Profit
- $23.21B+3.1%
- Op Income
- $10.02B
- Net Income
- $8.51B+1672.9%
- EPS
- $6.84+1700.0%
- OCF Growth
- -7.5%
- FCF Growth
- -8.2%
- 52W High
- $176.58
- 52W Low
- $116.88
- 50D MA
- $156.80
- 200D MA
- $142.22
- Beta
- 0.36
- RSI (14)
- 54
- Avg Volume
- 5.94M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Gilead reported strong third-quarter growth across HIV, oncology and liver disease, raised full-year guidance, and highlighted a still-robust pipeline despite a future Biktarvy pricing headwind from IRA negotiations.· October 29, 2026
- Base business sales rose 16% year over year to $8.2 billion, the strongest growth since 2015, led by HIV, Trodelvy and Livdelzi.
- Non-GAAP EPS was $2.55 versus $2.47 a year ago, and product gross margin expanded to 88% from 86%.
- HIV remained the core growth engine: HIV sales were $6.2 billion, Biktarvy reached 53% U.S. market share, and Yeztugo sales were $305 million.
- Trodelvy sales grew 42% year over year to $506 million, while Livdelzi sales jumped 93% to $203 million.
- Management raised 2026 base business sales guidance and reiterated full-year Yeztugo sales of about $1 billion, while flagging a 2028 Biktarvy revenue hit from CMS price setting.
Total product sales excluding Veklury were $8.2 billion, up 16% year over year; including Veklury, total product sales were $8.3 billion, up 13% year over year. HIV sales were $6.2 billion, up 18% year over year; Biktarvy sales were $4.1 billion, up 10%; Yeztugo sales were $305 million, up 31% sequentially and on track for about $1 billion full-year sales; Descovy sales were $1 billion, up 49%; Livdelzi sales were $203 million, up 93%; Trodelvy sales were $506 million, up 42%; and cell therapy sales were $355 million, down 18%. Product gross margin was 88% versus 86% in the prior-year quarter; R&D was $1.6 billion, up 19%; SG&A was $1.5 billion, up 14%; operating margin was 50%; and non-GAAP diluted EPS was $2.55 versus $2.47 a year ago. For 2026, Gilead now expects base business sales of $30.7 billion to $31.0 billion and total product sales of $31.0 billion to $31.3 billion, with Veklury still expected at about $300 million. Management now expects full-year non-GAAP loss per share of $1.20 to $0.85, while excluding acquired IPR&D and related financing costs plus nonrecurring other revenue, illustrative non-GAAP diluted EPS would be $8.75 to $9.10. Looking ahead to 2028, CMS set Biktarvy at $2,600 per 30-day supply, and management preliminarily expects about a $1.5 billion net impact to Biktarvy revenue in 2028; however, they still expect total HIV revenue, total product sales and EPS to grow in 2028 versus 2027.
Dan O’Day described the quarter as exceptional and said the business is showing strength, breadth and durability. He emphasized diversification across HIV, oncology and inflammation, and said the company is preparing for the next wave of launches, including weekly oral HIV treatment, broader PrEP options, anito-cel and new inflammation programs. He was also clearly critical of the CMS/IRA price-setting outcome for Biktarvy, arguing it does not reflect the medicine’s value and could discourage innovation, while reiterating that Gilead believes it can adapt to policy headwinds.
Andrew Dickinson said the quarter showed strong commercial and clinical execution alongside expense discipline. He pointed to 88% product gross margin, 50% operating margin, and higher R&D and SG&A driven partly by compensation accruals tied to financial outperformance and higher HIV promotional activity. He also updated capital return, saying Gilead returned about $1.4 billion to shareholders in the quarter, including $370 million of share repurchases, and had returned about 40% of free cash flow in the first three quarters of 2026. He gave detailed policy guidance as well, saying CMS set Biktarvy pricing at $2,600 per 30-day supply and that the company expects about a $1.5 billion net revenue impact in 2028, while still expecting total HIV revenue, total product sales and EPS to grow that year.
Analysts pressed on the mechanics and implications of the Biktarvy IRA pricing impact, and management said the $1.5 billion figure is a net 2028 impact that includes Medicare plus spillovers into Medicaid, 340B and other channels, and is mostly Medicare-related. Questions also focused on the weekly oral PrEP launch, where management said it should appeal to people who want long-acting prevention without injections and that it can build on existing Yeztugo access. On cell therapy, management addressed the partial clinical hold on KITE-753 by saying they are investigating a small number of Grade 3 and Grade 4 ICANS cases, with no Grade 5 events, while reaffirming that KITE-363 in autoimmune disease continues and that anito-cel remains on track for its December 23 PDUFA date. Analysts also asked about the oral IL-23 program and combination potential; management said it is still early and formulations are still being worked on.
The bull case from this call is that Gilead’s core businesses are still accelerating, with HIV, Trodelvy and Livdelzi all contributing to strong base-business growth. Management also outlined a deep pipeline across HIV, oncology and inflammation, including multiple near-term catalysts such as anito-cel, weekly oral HIV regimens and more inflammation data. Even with the Biktarvy pricing issue, management said the broader HIV franchise should keep growing and that total product sales and EPS should still increase in 2028.
The main risk highlighted on the call is the upcoming Biktarvy price reduction starting in 2028, which management estimates could reduce Biktarvy revenue by about $1.5 billion on a net basis. Cell therapy remains pressured by competition, and the company disclosed a partial clinical hold on KITE-753 because of Grade 3 and Grade 4 ICANS differences. Management also acknowledged that HIV market growth is not yet back to the usual 2% to 3% pace and that some Q3 inventory dynamics may make Q4 more modest than usual.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.8%
- Shares Outstanding
- 1.24B
- Float Shares
- 1.24B
of shares held by institutions
2,384 13F filers
Buy/sell ratio 0.19. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for GILD, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Ro KhannaHouse · CA17 | Sell | Aug 10, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jul 7, 26 | Filing → |
| Thomas Hawley TubervilleSenate · AL | Buy | May 10, 24 | Filing → |
| Thomas Hawley TubervilleSenate · AL | Buy | May 10, 24 | Filing → |
| Thomas Hawley TubervilleSenate · AL | Buy | May 10, 24 | Filing → |
| Alan ArmstrongSenate | Buy | Mar 27, 26 | Filing → |
| Jared MoskowitzHouse · FL23 | Buy | May 6, 26 | Filing → |
| Jared MoskowitzHouse · FL23 | Buy | May 6, 26 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Jan 27, 26 | Filing → |
| Val HoyleHouse · OR04 | Sell | Sep 23, 25 | Filing → |
| Val HoyleHouse · OR04 | Buy | Oct 29, 24 | Filing → |
| Jefferson ShreveHouse · IN06 | Sell | May 12, 25 | Filing → |
| Marjorie Taylor GreeneHouse · GA14 | Buy | Jun 6, 25 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | May 14, 25 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 125.25M | ▲ 3.40M |
| Vanguard Group Inc | 121.10M | ▲ 2.11M |
| Vanguard Capital Management LLC | 81.18M | ▲ 83.89K |
| State Street Corp | 60.95M | ▼ 261.58K |
| Fmr LLC | 58.27M | ▼ 8.61M |
| Invesco Ltd. | 38.66M | ▼ 1.16M |
| Capital World Investors | 35.93M | ▼ 5.06M |
| Vanguard Portfolio Management LLC | 35.69M | ▲ 369.65K |
| Geode Capital Management, LLC | 30.19M | ▲ 125.00K |
| Price T Rowe Associates Inc | 30.00M | ▲ 3.75M |
| Capital Research Global Investors | 23.98M | ▲ 4.59M |
| Morgan Stanley | 23.76M | ▼ 249.02K |
Held by 2,900 ETFs
Biggest fund positions in GILD by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | Mercier Johanna | other | 25,000 |
| Nov 16, 26 | Mercier Johanna | sell | 13,922 |
| Nov 16, 26 | Mercier Johanna | sell | 13,178 |
| Nov 16, 26 | Mercier Johanna | sell | 900 |
| Nov 16, 26 | Mercier Johanna | other | 25,000 |
| Nov 16, 26 | Dickinson Andrew D | sell | 3,000 |
| Nov 12, 26 | Kramer Kelly A. | other | 10,376 |
| Nov 12, 26 | Kramer Kelly A. | sell | 1,676 |
| Nov 12, 26 | Kramer Kelly A. | sell | 3,800 |
| Nov 12, 26 | Kramer Kelly A. | sell | 4,700 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our GILD coverage
Recent articles, reports, and earnings notes.

Gilead Sciences (GILD): HIV Strength Powers Growth, But Valuation Limits Upside
Gilead posted strong HIV-led growth, with base business sales up 16% and management raising full-year guidance. The stock still looks fairly valued near consensus, keeping the call at Hold.

ARIAD Pharmaceuticals IPO Preview: Historical Biotech, Current Filing Gap
ARIAD Pharmaceuticals, Inc. (NYSE: ARIA) is expected to list on 2026-08-10, but the price range has not been disclosed. The key question is not valuation yet—it is whether this is a real upcoming IPO filing or a historical company reference that still needs confirmation. Bull case: a recognizable biotech name; bear case: the current offering details are not yet verified.

Gilead Sciences, Inc. (GILD) gains on deep earnings beat analysis
Gilead Sciences, Inc. (GILD) gains after a stronger-than-expected earnings report, but the real story is deeper than the headline beat. This analysis breaks down revenue momentum, HIV and Yeztugo growth, acquisition-related charges, and what the latest guidance means for the stock.
Want a deeper read on GILD?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Worried investors are paying up for these stocks — some with up to 49% upside, analysts say
marketwatch.com · Nov 18
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
zacks.com · Nov 18
Gilead Sciences, Inc. (GILD) Presents at Jefferies Global Healthcare Conference 2026 Transcript
seekingalpha.com · Nov 17
Gilead Sciences, Inc. (GILD) Presents at UBS Global Biopharma Conference 2026 Transcript
seekingalpha.com · Nov 17
Gilead Sciences Maps Growth Beyond BIKTARVY With HIV, Cancer and Inflammation Drugs
marketbeat.com · Nov 17
Suffolk Celebrates Completion of Gilead Sciences Research Center With Ribbon Cutting
businesswire.com · Nov 17
Gilead Sciences Bets on HIV Prevention Growth Despite $1.5 Billion Biktarvy Headwind
marketbeat.com · Nov 17
These 3 Dividend Stocks Have Crushed the Market This Year. Here’s Why They Are Still Buys
fool.com · Nov 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.